Neogen (NEOG)
(Delayed Data from NSDQ)
$14.44 USD
+0.16 (1.12%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $14.45 +0.01 (0.07%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.44 USD
+0.16 (1.12%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $14.45 +0.01 (0.07%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Zacks News
Zimmer Biomet (ZBH) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions record year-over-year sales growth at CER.
CONMED (CNMD) Down on Q4 Earnings Miss, New System Hurts Sales
by Zacks Equity Research
CONMED's (CNMD) adjusted fourth-quarter sales and earnings reflect disruption due to implementation of a new warehouse management system.
Cardinal Health (CAH) Q2 Earnings Top, EPS Outlook Raised
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results benefit from the solid performance of the Pharmaceutical segment.
Accuray (ARAY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.
BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.
Quest Diagnostics (DGX) Q4 Earnings Top Estimates, Margin Down
by Zacks Equity Research
Improvement within Quest Diagnostics' (DGX) legacy base business contributes to Q4 performance.
McKesson (MCK) Q3 Earnings Surpass Estimates, EPS View Up
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2023 results benefit from segmental growth.
Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
Align Technology's (ALGN) lower scanner volume and ASPs are partially offset by higher services revenues from the larger installed base of scanners and increased non-system revenues.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about the strong performance of Neogen's (NEOG) Animal Safety and Food Safety segments.
Neogen (NEOG) Q2 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Growth across the Food Safety and Animal Safety segments drives Neogen's (NEOG) Q2 revenues.
Neogen (NEOG) Rises 7.9% Since Q1 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) recent product launches and strong global presence.
Neogen (NEOG) Benefits From Advanced Portfolio, Global Growth
by Zacks Equity Research
Barring Australia and China, solid international operations also buoy optimism for Neogen (NEOG).
HEXO (HEXO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
HEXO (HEXO) delivered earnings and revenue surprises of -250% and 19.23%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Neogen (NEOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Healthy Top-Line Growth Buoy Jabil (JBL) Q1 Earnings?
by Zacks Equity Research
Backed by solid demand in key end markets, diligent execution of operational plans and skillful management of supply chain dynamics, Jabil (JBL) is likely to record healthy fiscal first-quarter revenues.
Neogen's (NEOG) Synergize Disinfectant Now Widely Available
by Zacks Equity Research
Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.
Neogen (NEOG) Down 13.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen (NEOG) Q1 Earnings Top Estimates, Operating Margin Dips
by Zacks Equity Research
Neogen's (NEOG) allergen and environmental sanitation product lines decline due to reduced buying patterns from customers and supply chain disruptions of certain products.
Neogen (NEOG) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -6.25% and 2.51%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Launches Test for Detection of Cashew Allergen
by Zacks Equity Research
Neogen's (NEOG) new quantitative test shows a high level of specificity to very low levels of cashew protein (down to 0.2 ppm).
Neogen (NEOG) Finalizes Food Safety Business Merger With 3M
by Zacks Equity Research
The combination of Neogen (NEOG) and 3M's Food Safety division will capitalize on the ongoing growth trends in sustainability, food safety and supply chain integrity.
Phibro Animal Health (PAHC) Q4 Earnings Lag Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of -10% and 0.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.